avanafil avanafil avanafil is a pde5 inhibitor approved for erectile dysfunction by the fda on april 27, 2012 and by ema on june 21, 2013. avanafil is sold under the brand names stendra and spedra. it was invented at mitsubishi tanabe pharma, formerly known as tanabe seiyaku co., and licensed to vivus inc., which partnered with menarini group to commercialise spedra in over forty european countries, australia, and new zealand. metuchen pharmaceuticals obtained exclusive rights within the united states. avanafilavanafil is a pde5 inhibitorclinical datatrade namesstendraahfs/drugs.commonographmedlineplusa614010license data eu ema: by inn us dailymed: avanafil us fda: avanafil routes ofadministrationby mouthatc codeg04be10 (who) legal statuslegal status au: s4 (prescription only) uk: pom (prescription only) us: ℞-only eu: rx-only identifiers iupac name (s)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide cas number330784-47-9 ypubchem cid9869929iuphar/bps7448drugbankdb06237 ychemspider8045620 yuniidr5s136ivokeggd03217 ychebichebi:66876chemblchembl1963681 npdb ligande6l (pdbe, rcsb pdb)comptox dashboard (epa)dtxsid50186727 chemical and physical dataformulac23h26cln7o3molar mass483.96 g·mol−13d model (jsmol)interactive image smiles clc1c(oc)ccc(c1)cnc3nc(ncc3c(=o)ncc2ncccn2)n4(ccc4)co inchi inchi=1s/c23h26cln7o3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32h,2,4,9,11,13-14h2,1h3,(h,28,33)(h,27,29,30)/t16-/m0/s1 ykey:weajzxnpawbcoa-inizcteosa-n y ny (what is this?) (verify) avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus cavernosum penis. other similar drugs are sildenafil, tadalafil and vardenafil. the advantage of avanafil is that it has very fast onset of action compared with other pde5 inhibitors. it is absorbed quickly, reaching a maximum serum concentration in about thirty to forty-five minutes. about two-thirds of the participants were able to engage in sexual activity within fifteen minutes. medical use avanafil is used to treat erectile dysfunction (ed). adverse effects although avanafil is generally well tolerated, dose dependent adverse effects can occur. the most common adverse effects include headache, flushing, nasopharyngitis, nasal congestion, and back pain. while it is also uncommon, there is a potential for visual disturbances to occur in patients. mechanism of action avanafil inhibits phosphodiesterase-5, preventing the degradation of cgmp. the increased levels of cgmp causes vasodilation, resulting in an increased blood flow in the penis. avanafil's mechanism of action takes places once nitric oxide is released, in association with sexual stimulation. synthesis avanafil can be synthesized from a benzylamine derivative and a pyrimidine derivative: